Ehlers-Danlos syndrome, fibronectinemic type

disease
On this page

Also known as EDS XEDS10 (formerly)Ehlers-Danlos syndrome type 10Ehlers-Danlos syndrome type 10 (formerly)Ehlers-Danlos syndrome with platelet dysfunction from fibronectin abnormalityEhlers-Danlos syndrome, fibronectin-deficientEhlers-Danlos syndrome, type X (formerly)

Summary

Ehlers-Danlos syndrome, fibronectinemic type (MONDO:0009158) is a disease. A subtype of inherited bleeding disorder, platelet-type — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameEhlers-Danlos syndrome, fibronectinemic type
Mondo IDMONDO:0009158
MeSHC565600
OMIM225310
Orphanet75501
SNOMED CT83586000
UMLSC1857038
MedGen346497
GARD0008508
Is cancer (heuristic)no

Also known as: EDS X · EDS10 (formerly) · Ehlers-Danlos syndrome type 10 · Ehlers-Danlos syndrome type 10 (formerly) · Ehlers-Danlos syndrome with platelet dysfunction from fibronectin abnormality · Ehlers-Danlos syndrome, fibronectin-deficient · Ehlers-Danlos syndrome, type X (formerly)

Disease family

This is a subtype of inherited bleeding disorder, platelet-type. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorderhemorrhagic diseaseinherited bleeding disorder, platelet-typeEhlers-Danlos syndrome, fibronectinemic type

Related subtypes (27): gray platelet syndrome, primary release disorder of platelets, platelet-type von Willebrand disease, platelet-type bleeding disorder 16, platelet-type bleeding disorder 17, Bernard-Soulier syndrome, Scott syndrome, congenital thrombotic thrombocytopenic purpura, Quebec platelet disorder, platelet-type bleeding disorder 12, platelet-type bleeding disorder 10, platelet-type bleeding disorder 8, platelet-type bleeding disorder 14, platelet-type bleeding disorder 9, platelet-type bleeding disorder 11, platelet-type bleeding disorder 15, platelet-type bleeding disorder 18, platelet-type bleeding disorder 19, platelet-type bleeding disorder 20, macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss, cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder, bleeding disorder, platelet-type, 24, bleeding disorder, platelet-type, 22, bleeding disorder, platelet-type, 21, Glanzmann thrombasthenia, bleeding diathesis due to thromboxane synthesis deficiency, bleeding disorder, platelet-type, 25

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.